Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

Sam and Danni start Friday on Radio 1.